

New Specialty Drug Site-of-Care Policy

Update: Ocrevus added effective 10/1/2020

PHP encourages a strong relationship between our Members and Providers, while providing cost-effective care. Beginning **July 1, 2019**, to provide consistency and to align with industry practices, PHP is implementing new site-of-care requirements. The following list of medications require administration to occur in a non-facility setting, such as in your office or by a home infusion provider.

Medication brand names	Generic name	HCPCS codes
Benlysta	belimumab	J0490
Xgeva, Prolia	denosumab	J0897
Privigen, GamaSTAN, Cuvitru, Bivigam, Gammaplex, Hizentra, Gamunex-C, Gammaked, Carimune, Octagam, Gammagard, Flebogamma, Hyqvia, <i>others</i>	immune globulin	J1459, J1460, J1555, J1556, J1557, J1559, J1560, J1561, J1562, J1566, J1568, J1569, J1572, J1575, J1599
Simponi Aria	golimumab	J1602
Remicade, Inflectra, Renflexis	infliximab	J1745, Q5103, Q5104
Xolair	omalizumab	J2357
Stelara	ustekinumab	J3357
Entyvio	vedolizumab	J3380
Ocrevus	ocrelizumab	J2350

Place of service exceptions may be made when submitting a prior approval request. **Prior approval of the medication is required before outpatient administration, regardless of the site of service.** Members with active authorizations are not subject to the program requirements until prior approval renewal on or after July 1, 2019. This program does not include oncology medications. This program does not apply to the self-funded SHS products (groups L0001269 or L0000264).

If you have questions regarding the PHP site-of-care policy, please visit our website at PHPMichigan.com/Providers or contact PHP Customer Service at 800.832.9186.